SARS-CoV-2-Associated Acute Transverse Myelitis in Panama with Analysis of 38 Cases Reported Worldwide During COVID-19 (preprint)

Background: Acute transverse myelitis (ATM) is a rare neurological complication of viral infections and vaccinations. We report a 72-year-old man with SARS-CoV-2-associated cervicothoracic ATM in Panama, and analyze the results of a bibliographic investigation on myelitis during COVID-19.Methods: Systematic review of 38 patients with COVID-19-associated myelitis from 19 countries published between March and October 2020.Findings: All patients had typical features of ATM with acute onset of paralysis, sensory level, and sphincter deficits due to spinal cord lesions demonstrated by imaging. There were 21 men (55%) and 17 women (age range, 21-73 years; mean age, 49 years) with two age peaks at 29 and 58 years, excluding two pediatric cases. Longitudinally-extensive ATM involved cervicothoracic segments in 14 cases (42%), localized ATM lesions affected cervical (10 cases) and thoracic cord segments (7 cases). Acute disseminated encephalomyelitis (ADEM) occurred in 7 patients, mainly women (67%) with ages ranging from 27 to 64 years. Two patients had blindness due to myeloneuritis optica, and 2 had acute motor axonal neuropathy.Interpretation: Acute myelitis is an unexpectedly frequent neurological complication of COVID-19. Short latency from onset of infection to first neurological symptoms may indicate a direct neurotropic effect of SARS-CoV-2 during the initial infection, while longer latency of the post-infectious neurological complications may be mediated by the host’s response to the virus. The immune mechanisms causing ATM remain unknown. It is conceivable that common antigens inducing ATM may occur in both SARS-CoV-2 and in the ChAdOx1 nCoV-19 Chimpanzee adenovirus vaccine. (ClinicalTrials.gov Identifier: NCT04324606). Funding: None.Declaration of Interests: The authors declare no competing interests.

Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey.

BACKGROUND: The emergence of COVID-19 and its vertiginous spreading speed represents a unique challenge to neurologists managing multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). The need for data on the impact of the virus on these patients grows rapidly. There is an urgent necessity of sharing information to enable evidence-based decision making on the clinical management. There are no data on what physicians are doing on clinical practice in Latin American countries. AIM: to investigate current management opinion of Latin American MS and/or NMOSD expert neurologists based on their experience and recommendations. METHODS: we developed a voluntary web-based survey based on hypothetical situations that these patients may encounter, while taking into account the potential risk of developing severe COVID-19 infection. RESULTS: 60% of the experts had the possibility of monitoring their patients by telemedicine. Most neurologists postpone magnetic resonance. Laboratory blood tests delay is associated with the type of treatment. Platform therapies, dimethyl-fumarate and natalizumab are considered safe options to initiate in naive patients. CONCLUSION: decision-making about MS and NMOSD patients has become even more complex in order to adapt to the COVID-19 pandemic. Risks and benefits should be taken into consideration throughout the patient follow-up.